Table 6: Overall search results Search 1 Search 2 Search 3 Search 4 Database – fracture risk – role of DXA – anti-resorptives – cost-effects MEDLINE (Ovid SP) 88 115 599 25 The Cochrane Library 116 241 111 13 Centre for Reviews and 3 13 12 5 Dissemination Sub Total 207 369 722 43 Duplicates Removed 55 35 80 7 Total 152 334 642 36 1st Screen: 19 in meta-analysis 237 irrelevant 486 wrong intvn 29 wrong intvn Excluded studies from 1 animal study 5 wrong publication 1 non-English 4 wrong patients title search: 39 BMD intvns 14 wrong patients 13 wrong patients 6 duplicates 17 wrong comparator 20 wrong comparator 9 short follow-ups 54 wrong publication 1 metastatic brca 16 irrelevant 9 not AIs 7 not breast cancer 14 wrong outcomes 36 wrong pub Papers retrieved 11 64 48 3 2nd Screen: 1 superseded 1 duplicate 4 irrelevant 1 wrong patients Excluded studies from 1 could not get 2 could not get 1 could not get full papers 1 wrong outcome 4 non-English 3 duplicates 3 not DXA 4 systematic reviews 26 wrong topic 12 trial stages 1 superseded 11 superseded 1 wrong comparator 19 wrong pub Included studies 8 7 13 2 Studies added 0 0 1 1 Total studies 8 7 14 3 AI = aromatase inhibitor, BMD = bone mineral density, DXA = dual energy X-ray absorptiometry, The total number of studies found on the clinical registers and HTA websites was 76. After duplicates were removed (4), there were no relevant studies to add to the above search results. Data extraction and analysis For the included studies, data were extracted from full text articles on year of publication, study type, country of research, study design, follow-up period, aromatase inhibitor, bone-loss treatment, comparative groups and key results. Summary tables were completed with appraisal of the evidence and are provided in Appendix C. Appraisal of the evidence Appraisal of the evidence was conducted at 3 stages: Stage 1: Appraisal of the applicability and quality of individual studies included in the review.
Table 6: Overall search results Database Search 1 – fracture risk Search 2 – role of DXA Search 3 – anti-resorptives Search 4 – cost-effects MEDLINE (Ovid SP) 88 115 599 25 The Cochrane Library 116 241 111 13 Centre for Reviews and Dissemination 3 13 12 5 Sub Total 207 369 722 43 Duplicates Removed 55 35 80 7 Total 152 334 642 36 1st Screen: Excluded studies from title search: 19 in meta-analysis 1 animal study 39 BMD intvns 6 duplicates 9 short follow-ups 1 metastatic brca 9 not AIs 7 not breast cancer 14 wrong outcomes 36 wrong pub 237 irrelevant 5 wrong publication 14 wrong patients 17 wrong comparator 486 wrong intvn 1 non-English 13 wrong patients 20 wrong comparator 54 wrong publication 16 irrelevant 29 wrong intvn 4 wrong patients Papers retrieved 11 64 48 3 2nd Screen: Excluded studies from full papers 1 superseded 1 could not get 1 wrong outcome 1 duplicate 2 could not get 4 non-English 3 not DXA 26 wrong topic 1 superseded 1 wrong comparator 19 wrong pub 4 irrelevant 1 could not get 3 duplicates 4 systematic reviews 12 trial stages 11 superseded 1 wrong patients Included studies 8 7 13 2 Studies added 0 0 1 1 Total studies 8 7 14 3 AI = aromatase inhibitor, BMD = bone mineral density, DXA = dual energy X-ray absorptiometry, The total number of studies found on the clinical registers and HTA websites was 76. After duplicates were removed (4), there were no relevant studies to add to the above search results. Data extraction and analysis For the included studies, data were extracted from full text articles on year of publication, study type, country of research, study design, follow-up period, aromatase inhibitor, bone-loss treatment, comparative groups and key results. Summary tables were completed with appraisal of the evidence and are provided in Appendix C. Appraisal of the evidence Appraisal of the evidence was conducted at 3 stages: Stage 1: Appraisal of the applicability and quality of individual studies included in the review.